Celldex Therapeutics Profit Margin

Celldex Therapeutics (CLDX) currently reports a profit margin of -268385.71% as of June 2026. That compares with -3446.88% in the prior-year period — down 7686.3% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Celldex Therapeutics's profit margin history and peer comparisons.

Celldex Therapeutics's profit margin decreased from -3446.88% to -268385.71% — a 7686.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Celldex Therapeutics's profit margin of -268385.71% is lower than the Healthcare sector average of 21.34%. That is roughly 1258047.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Celldex Therapeutics's current -268385.71% should be judged against Healthcare norms (sector average: 21.34%) and against CLDX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -268385.71%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Celldex Therapeutics, and consider following CLDX for alerts when major investors trade the stock.